Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex ...

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...

The next viral Instagram trend is finally here, and it’s a good one! It’s called “your algorithm” and it creates a cool ...

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

How will the work of biographers change as letters, diaries and photographs are replaced by emails, texts and snapshots on ...

Southern Alberta farmers receive international recognition from multi-billion dollar PepsiCo at the Global Farmer Awards.

Boston-based Solel Partners initiated a position in Braze stock last quarter, buying 745,900 shares worth an estimated $21.2 million. The transaction value represented 4.1% of reportable assets under ...

MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ:MDAI) reported third quarter earnings results on November 11 th . Highlights since our previous update include several presentations ...